Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.55 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.55 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | OGA | O60502 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1309502 | 0.90 | HTT (0.56) | PIK3CAPIK3CBPIK3CGHTTLMNA | |
| SCHEMBL1309956 | 0.82 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGHTTOGA | |
| SCHEMBL1309834 | 0.81 | PIK3CA (0.58) | PIK3CAPIK3CBPIK3CGHTTMTOR | |
| SCHEMBL13406351 | 0.81 | PIK3CA (0.67) | PIK3CAPIK3CBPIK3CGHTTOGA | |
| SCHEMBL1310300 | 0.81 | MEN1 (0.54) | PIK3CAPIK3CBPIK3CGHTTOGA | |
| SCHEMBL1310511 | 0.80 | CYP1A2 (0.58) | OGALMNAALDH1A1KDM4EALOX15 | |
| SCHEMBL1309997 | 0.80 | PIK3CA (0.73) | PIK3CAPIK3CBPIK3CGMTOR | |
| SCHEMBL1311052 | 0.80 | PIK3CA (0.57) | PIK3CAPIK3CBPIK3CGHTTMEN1 | |
| SCHEMBL1310482 | 0.80 | PIK3CA (0.61) | PIK3CAPIK3CBPIK3CGHTTLMNA | |
| SCHEMBL14504170 | 0.80 | OGA (0.53) | PIK3CAPIK3CBPIK3CGHTTOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-8921361-B2 | Triazine, pyrimidine and pyridine analogs and their use as therapeutic agents and diagnostic probes | UNIVERSITY OF BASEL (CH) | 2014-12-30 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2011-11-10 | — | — | US | disclosed |
| EP-2364302-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | University of Basel (CH) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052569-A2 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | UNIVERSITY OF BASEL (CH) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110275762-A1 | TRIAZINE, PYRIMIDINE AND PYRIDINE ANALOGS AND THEIR USE AS THERAPEUTIC AGENTS AND DIAGNOSTIC PROBES | MTOR, PIK3CA, PIK3CD | PIK3CA 2/4885PIK3CB 7/4885PIK3CG 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.